LABA Safety Studies, REMS Are Next Topics For Sponsors, FDA After Relabeling
Executive Summary
Discussions about how best to study the safety of long-acting beta agonists are ready to resume now that FDA has issued a revised label for the drug class
You may also be interested in...
Foradil Completes LABAs’ Exit From Risk Evaluation and Mitigation Strategies
FDA says Novartis’ assessment of the long-acting beta agonist’s REMS, which consisted only of a communication plan, shows the “plan, and therefore the REMS, has met its goal.”
FDA Supersizes Its Order For LABA Safety Studies
The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.
Novartis COPD Drug Wil Test The LABA Safety Waters During Advisory Panel Review
Given the known risks of long-acting beta-2 agonists, a safety discussion seems likely when the Pulmonary-Allergy Drugs Advisory Committee meets to review Novartis' Arcapta Neohaler (indacaterol maleate).